Monday, 25 Sep 2017

You are here

New Zoster Vaccine Recommended by FDA Panel

Reuters reports that the Food and Drug Administration (FDA) advisory panel has voted 11-0 in favor of the safety and efficacy and ultimate approval of GlaxoSmithKline’s Shingrix shingles vaccine for use in adults aged 50 and over.

The proposed inactive vaccine against H. zoster (HZ) was previously reported to be more effective than the current live vaccine Zostavax made by Merck. (https://buff.ly/2y6zuvg)

The herpes zoster beta subunit vaccine was shown to be more than 90% effective (for 4+ years) in HZ prevention and post-herpetic neuralgia prevention, especially in those over age 70 yrs. - claims that exceed that seen with the current vaccine. 

Shingrix has the advantage of being an inactive (non-live) virus vaccine - that can be given to those who are immunosuppressed or receiving TNF inhibitors or other biologic agents.  Shingrix has not been studied in those who are immunosuppressed or receiving TNF inhibitors or other biologic agents.

GSK is forecasting sales for this product to reach $1 billion by 2023. In contrast, Zostavax, approved in 2006, is expected to generate sales of about $730 million this year. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

DSB Reports & Updates – August 2017

This Drug Safety Bulletin address FDA delay of baricitinib, etanercept effective at room temperature, Consumer Reports features on drug safety, no association between Alzheimer's and PPIs, AHRQ review of opioid drug safety, FDA safety abeling changes, drug shortages and more. 

Canakinumab Patients have Lower Risk of Lung Cancer

The CANTOS trial has shown that interleukin 1β inhibition by Canakinumab (CAN) resulted not only in a reduction of cardiovascular deaths but also significantly decreased the incidence and death from lung cancer.

Shingles Vaccine Studies in A&R

The current issue of Arthritis & Rheumatology features an editorial and two novel articles on the herpes zoster vaccine. Kevin Winthrop and colleagues report on the results of a phase II trial wherein 112 patients about to begin tofacitinib therapy were vaccinated with the live-virus zoster vaccine (LZV).

Non-Tuberculous Mycobacterial Infections - Diagnosis and Management for the Rheumatologist

Non-Tuberculous Mycobacterial infections are among the most frequently reported opportunistic infections in the setting of biologic therapy. While there are hundreds of NTM species, only a minority are clinically relevant. In this review, I'll address important NTM diagnosis and management issues relevant to patients receiving biologic therapy.

 

August 2nd AAC Meeting: FDA Concerns Over Sirukumab Deaths

On August 2, the US Food and Drug Administration (FDA) will convene a hearing of the Arthritis Advisory Committee (AAC) to review the safety of the novel IL-6 inhibitor, sirukumab, being developed by Janssen (Johnson & Johnson). Specifically, FDA reviewers have concerns over the number of deaths on sirukumab compared to those receiving placebo.